Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Amgen Hormone-Imbalance Drug Shows Positive Results in Late-Phase Study

Monday, March 09, 2015   (0 Comments)
Share |

From The Wall Street Journal
By Maria Armental

 

Experimental treatment is for secondary hyperparathyroidism in patients with chronic kidney disease

A late-phase clinical study of Amgen Inc.’s experimental treatment for secondary hyperparathyroidism in patients with chronic kidney disease showed a higher percentage of patients responded to its treatment.

[Read article online]


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership.com®  ::  Legal